Clinical Trial Update: DNP-Modified Autologous Tumor Cell Vaccine for Resectable Non-Small Cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial of AVAX's DNP-modified autologous tumor cell vaccine for completely resectable non-small cell lung cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• DNP-Modified Autologous Tumor Cell Vaccine (DNP-modified autologous tumor cell vaccine)

Snippet

Sponsor: AVAX Technologies | Conditions: Non-Small Cell Lung Cancer - Completely Resectable | Phase 1, Phase 2 | Status: TERMINATED